Lock anti-CTLA4 antibody - PrecisemAb
Alternative Names: Lock-CTLA4 - PrecisemAbLatest Information Update: 30 Aug 2022
At a glance
- Originator PrecisemAb
- Class Antineoplastics; Biobetters; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Lymphoma
Most Recent Events
- 03 Aug 2022 Lock anti-CTLA4 antibody - PrecisemAb is available for licensing as of 03 Aug 2022. https://www.precisemab.com.tw/Partners
- 03 Aug 2022 Preclinical trials in Lymphoma in Taiwan (Parenteral) as of August 2022 (PrecisemAb pipeline, August 2022)